On November 13, CDE official website data show that Sichuan Guo for the pharmaceutical osteochemical triol softgel class 4 imitation market application was accepted, is currently in review and approval.
is a top1 variety of vitamin drugs, in 2019 in China's public medical institutions terminal sales have exceeded 2 billion yuan, the current variety has no enterprise evaluation.
Figure 1: Sichuan State for pharmaceutical osteosterol softgel declaration Source: CDE official website Figure 2: Sales of osteolytic triol Source: Minernet China's public medical institutions terminal competition pattern MiNet data show that in China's urban public hospitals Among the end-vitamin TOP20 varieties of county-level public hospitals, urban community centers and township hospitals (China's public medical institutions), osteotisol ranked first with sales of more than 2 billion yuan, with a growth rate of 7.88% in the first half of 2020.
Figure 3:2020H1 osteolytic triol enterprise competition pattern source: Minet China's public medical institutions terminal competition pattern market domestic osteotisanol only Zhengda Pharmaceutical (Qingdao) was approved, the product is softgels, the enterprise also submitted a consistent evaluation of supplementary applications in July this year, is currently in review and approval.
From the market pattern, domestic brands have occupied half of the mountain, imported brands only Roche (glue pills) can compete with it, but Roche's market share has a gradual decline, in the first half of 2020 only 44.5%.
, only AbbVie has received import approval, and there are currently no domestic generics.
Currently osteolycol imitation listing applications, concentrated in softgels and ointments, Sichuan Guo for pharmaceutical, Henan Taifeng biotechnology declared the softgel 4 types of imitation listing, is currently in review and approval;
source: CDE official website, Mienet database